Abstract
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease with progressive muscular wasting and paralysis due to loss of motor neurons in the primary motor cortex, brainstem and spinal cord. Alterations of transcriptional activity due to an unbalance of the activity of histone acetyl transferases (HAT) and histone deacetylases (HDACs) have been described in a variety of neurodegenerative conditions in vitro and in vivo. HDACs can be grouped into four different classes with distinct cellular localization and functions. HDAC inhibitors have recently been discovered as potential neuroprotective drugs for the treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). A major limitation, however, lies in the broad spectrum of action of currently available HDAC inhibitors causing a variety of toxic side effects.
Keywords: Amyotrophic lateral sclerosis, neurodegeneration, transcriptional regulation, histone deacetylases, HDAC inhibitors, sirtuins
CNS & Neurological Disorders - Drug Targets
Title: Histone Deacetylation and Motor Neuron Degeneration
Volume: 9 Issue: 3
Author(s): S. Schmalbach and S. Petri
Affiliation:
Keywords: Amyotrophic lateral sclerosis, neurodegeneration, transcriptional regulation, histone deacetylases, HDAC inhibitors, sirtuins
Abstract: Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease with progressive muscular wasting and paralysis due to loss of motor neurons in the primary motor cortex, brainstem and spinal cord. Alterations of transcriptional activity due to an unbalance of the activity of histone acetyl transferases (HAT) and histone deacetylases (HDACs) have been described in a variety of neurodegenerative conditions in vitro and in vivo. HDACs can be grouped into four different classes with distinct cellular localization and functions. HDAC inhibitors have recently been discovered as potential neuroprotective drugs for the treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). A major limitation, however, lies in the broad spectrum of action of currently available HDAC inhibitors causing a variety of toxic side effects.
Export Options
About this article
Cite this article as:
Schmalbach S. and Petri S., Histone Deacetylation and Motor Neuron Degeneration, CNS & Neurological Disorders - Drug Targets 2010; 9 (3) . https://dx.doi.org/10.2174/187152710791292684
DOI https://dx.doi.org/10.2174/187152710791292684 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Preface
Central Nervous System Agents in Medicinal Chemistry Alternative Splicing: A Promising Target for Pharmaceutical Inhibition of Pathological Angiogenesis?
Current Pharmaceutical Design New Trends and Advances in Oral and Maxillofacial Imaging
Current Medical Imaging Minocycline: Neuroprotective Mechanisms in Parkinsons Disease
Current Pharmaceutical Design The Role of the Oxysterol/EBI2 Pathway in the Immune and Central Nervous Systems
Current Drug Targets From Stem Cells to Dopamine Neurons: Developmental Biology Meets Neurodegeneration
CNS & Neurological Disorders - Drug Targets The Cannabinoids Switch of Oxidative Stress: A Double-Edged Sword
Mini-Reviews in Organic Chemistry Cannabinoids and Neuro-Inflammation: Regulation of Brain Immune Response
Recent Patents on CNS Drug Discovery (Discontinued) The Click Test: A Novel Tool to Quantify the Age-Related Decline of Fast Motor Sequencing of the Thumb
Current Aging Science Targeting Astrocytes for Treatment in Amyotrophic Lateral Sclerosis
Current Pharmaceutical Design Amine Oxidase Inhibitors and Development of Neuroprotective Drugs
Current Neuropharmacology Prediction of Gene Co-Expression by Quantifying Heterogeneous Features
Current Bioinformatics The Multiple Layers of Signaling Selectivity at Protease-Activated Receptors
Current Pharmaceutical Design Inflammation as a Therapeutic Target in Acute Ischemic Stroke Treatment
Current Topics in Medicinal Chemistry Cation-Responsive MRI Contrast Agents Based on Gadolinium(III)
Current Inorganic Chemistry (Discontinued) A Common Biological Mechanism in Cancer and Alzheimers Disease?
Current Alzheimer Research Recent Advances in the Synthesis of 1,3-Azoles
Current Topics in Medicinal Chemistry Beneficial Effects of Dietary Supplements Against Mitochondrial Dysfunction and Apoptosis in Neurodegenerative Diseases
Current Pharmacogenomics and Personalized Medicine Neuroimmune Crosstalk in CNS Disorders: The Histamine Connection
Current Pharmaceutical Design Computer Aided Drug Design for Multi-Target Drug Design: SAR /QSAR, Molecular Docking and Pharmacophore Methods
Current Drug Targets